Payment overview · 2025
General Payments
$708.60
34 reported records · 14 companies
Healthcare provider profile · identity verified
Kaleb Evan Grimes
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CORDOVA, TN · NPI 1609599430
Verified facts
What the public records show
CMS Open Payments records show Kaleb Evan Grimes received $708.60 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.32 | 25.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.45 | 11.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.94 | 10.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.40 | 9.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.34 | 9.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.49 | 4.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.97 | 4.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.41 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.16 | 4.1% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.58 | 3.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.87 | 3.4% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.17 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.33 | 2.7% | 1 | 2025 |
| Athena Bioscience, LLC | Unresolved — no canonical attribution shown | $19.17 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $708.60 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $112.76 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.46 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $99.30 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $69.40 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.34 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.17 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $32.97 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.58 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.87 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| NEXICLON XR Normalized: nexiclon xr |
Drug | Athena Bioscience, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
88 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 309 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 78 |
| Gabapentin | Gabapentin | 196 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 58 |
| Losartan Potassium | Losartan Potassium | 158 | 66 |
| Alprazolam | Alprazolam | 157 | 49 |
| Methylprednisolone | Methylprednisolone | 137 | 124 |
| Lisinopril | Lisinopril | 128 | 48 |
| Ozempic | Semaglutide | 119 | 36 |
| Omeprazole | Omeprazole | 116 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 43 |
| Meloxicam | Meloxicam | 112 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 49 |
| Furosemide | Furosemide | 108 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 51 |
| Metformin Hcl | Metformin Hcl | 97 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 96 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 37 |
| Mounjaro | Tirzepatide | 88 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 21 |
| Prednisone | Prednisone | 83 | 61 |
| Montelukast Sodium | Montelukast Sodium | 78 | 37 |
| Potassium Chloride | Potassium Chloride | 78 | 31 |
| Famotidine | Famotidine | 76 | 35 |
| Azithromycin | Azithromycin | 70 | 59 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 29 |
| Jardiance | Empagliflozin | 59 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 24 |
| Carvedilol | Carvedilol | 54 | 21 |
| Allopurinol | Allopurinol | 51 | 18 |
| Simvastatin | Simvastatin | 51 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 16 |
| Methocarbamol | Methocarbamol | 46 | 24 |
| Amoxicillin | Amoxicillin | 45 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 42 |
| Pregabalin | Pregabalin | 44 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Fluconazole | Fluconazole | 42 | 27 |
| Glimepiride | Glimepiride | 42 | 18 |
| Sertraline Hcl | Sertraline Hcl | 42 | 19 |
| Ondansetron Odt | Ondansetron | 41 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 14 |
| Tramadol Hcl | Tramadol Hcl | 38 | 18 |
| Clonidine Hcl | Clonidine Hcl | 37 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 13 |
| Eliquis | Apixaban | 36 | 16 |
| Promethazine Hcl | Promethazine Hcl | 36 | 14 |
| Trazodone Hcl | Trazodone Hcl | 36 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Meclizine Hcl | Meclizine Hcl | 34 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 15 |
| Clonazepam | Clonazepam | 30 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 13 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Atenolol | Atenolol | 27 | 13 |
| Baclofen | Baclofen | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $708.60 · 34 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Fluad, Flucelvax, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NEXICLON XR, NUPLAZID, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, Wegovy, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error